Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UNGUT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
EV20/NMS-P945
|
|||||
| Synonyms |
EV20-NMS-P945; EV20 NMS-P945
Click to Show/Hide
|
|||||
| Organization |
University of Chieti-Pescara
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 6 Indication(s)
Gastric cancer [ICD11:2B72]
Clinical candidate
Head and neck cancer [ICD11:2B60-2B6E]
Clinical candidate
Melanoma [ICD11:2C30]
Clinical candidate
Ovarian cancer [ICD11:2C73]
Clinical candidate
Pancreatic cancer [ICD11:2C10]
Clinical candidate
Prostate cancer [ICD11:2C82]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
3.6
|
|||||
| Antibody Name |
EV20
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (ERBB3)
|
Antigen Info | ||||
| Payload Name |
NMS-P528
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Cathepsin-cleavable peptidic linker with self-immolating spacer
|
Linker Info | ||||
| Combination Type |
NMS-P945
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.